Oncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program
25 1월 2024 - 4:00PM
Business Wire
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ;
Mnemonic : ALOPM) (Paris:ALOPM), a biopharmaceutical company
specializing in precision medicine for the treatment of resistant
and metastatic cancer, is pleased to announce that it has receive
notification of the allocation of financial support from the
European Regional Development Fund (ERDF) under the FEDER-SSE+
program for Bourgogne Franche-Comté and Massif du Jura 2021-2027
program (Action “PR1-RSO1.1-TA1 - Soutenir les projets de recherche
collaboratifs dans les domaines de la stratégie de spécialisation
intelligente” (Supporting collaborative research projects in the
fields covered by the smart specialisation strategy)), aimed at
improving research and innovation.
Program COMETE (moleCular radiOtherapy for METastatic Colorectal
and gastric cancErs) is an application to a regional FEDER-FSE+
call for projects. It relates to the development of a
radiotheranostic molecules portofolio for the treatment of advanced
digestive cancers. The aim of the project is to develop one
radiotheranostic candidate to pre-clinical dosimetry studies. The
COMETE project is supported by OPM, the Centre de Lutte Contre le
Cancer (CGFL) and the Institut de Chimie (ICMUB), all based in
Dijon.
ERDF is one of the European Union's main funding programs,
designed to promote economic, social and territorial cohesion
between regions.
The key objective of ERDF is to strengthen the competitiveness
and cohesion of European regions.
ERDF is providing the COMETE project with a grant totalling a
maximum of €7.8m (for a total project cost of €9.2m), i.e. around
75% of the eligible amount, including €2.1m for OPM, over a
period of 5 years. It will contribute to progress research and
development of a portfolio of radiotheranostic molecules to the
pre-clinical stage. The internal vectorised radiotherapy (IVR)
molecules will be developed to treat advanced digestive cancers,
and their diagnostic companions will be developed to diagnose and
monitor the same patients before and after IVR treatment. This
contribution from ERDF to the COMETE program strengthens Oncodesign
Precision Medicine's position as a major player in the
biotechnology sector in indications with a high medical need. This
project, which will be developed in the Bourgogne Franche-Comté
region, is part of a strong regional dynamic in favour of the
development of biotechnologies and precision medicine.
Philippe GENNE, Chairman and CEO of Oncodesign Precision
Medicine said: "We are honoured by the faith demonstrated by
the Bourgogne Franche Comté region through this grant. This is a
significant step forward for the development of our
radiotheranostics portfolio. This approach is extremely useful for
the treatment of metastatic cancers, which are currently difficult
to cure. We are very pleased to be able to effectively launch the
PROMETHE® industrial chain, which, like the Pharmimage cluster of
excellence, will be a regional and national strength in this
fast-evolving field of medicine.”
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Promethe for the design and
selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. A first drug candidate based on the
Nanocyclix® technology entered the clinical phase in 2022, in
partnership with SERVIER (which exercised its option for an
exclusive worldwide license on the program) to treat Parkinson's
disease. OPM-101 is OPM's second candidate to enter the clinic, in
the treatment of chronic immuno-inflammatory diseases. Finally, OPM
is also collaborating with Servier to discover new therapeutic
targets for the treatment of pancreatic adenocarcinoma based on its
OncoSNIPER technology. In addition, OPM is seeking a partner for
Florepizol, a radiotracer specific for the mutated EGFR target,
which has successfully completed Phase I. Finally, OPM has a
significant portfolio of early-stage projects with Nanocyclix® and
Promethe in oncology. With this portfolio of molecules and
diversified therapeutic targets, OPM's mission is to discover
effective therapies to treat resistant and advanced cancers. Based
in Dijon, at the heart of the university and hospital cluster, OPM
has 25 employees.
More info at: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124370445/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
